obsolete_common variable immunodeficiency: ['A hypogammaglobulinemia that is results in insufficient production of antibodies needed to respond to exposure of pathogens and is characterized by low Ig levels with phenotypically normal B cells that can proliferate but do not develop into Ig-producing cells. Patients with common variable immunodeficiency have marked reduction in serum levels of both immunoglobulin G (IgG) and immunoglobulin A (IgA); about half of these patients also have reduced immunoglobulin M (IgM).', 'A primary immunodeficiency characterized by low levels or absence of all the immunoglobulin classes and lack of B-lymphocytes or plasma cells. It results in recurrent bacterial infections. Complications include autoimmune phenomena and cancer development.', 'Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.']
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
119 |
4. Check minimum number of eventsNone |
119 |
5. Include endpointsNone |
119 |
6. Filter based on genotype QC (FinnGen only) |
119 |
Control definitions (FinnGen only)
- Control exclude
- D3_IMMUNEMECHANISM
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other or unspecified common variable immunodeficiency
based on the number of shared cases.
Similar with more cases:
- Common variable immunodeficiency
- Immunodeficiencies
- Certain disorders involving the immune mechanism
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 443 | 255 | 186 |
| Only index persons | 415 | 243 | 172 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 46.95 | 48.76 | 44.63 |
| Only index persons | 45.68 | 47.31 | 43.38 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 119 | 77 | 42 |
| Unadjusted period prevalence (%) | 0.02 | 0.03 | 0.02 |
| Median age at first event (years) | 47.58 | 48.76 | 45.42 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 104
- Matched controls
- 1039
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D83.9
ICD-10 Finland
Common variable immunodeficiency, unspecified
+∞
113.2
87
*
120
Kela drug reimbursment
Hypogammaglobulinaemia
+∞
67.1
57
*
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
+∞
64.4
55
*
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
+∞
55.2
48
*
D83.8
ICD-10 Finland
Other common variable immunodeficiencies
+∞
35.5
32
*
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
27.3
25
*
D83.0
ICD-10 Finland
Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
+∞
26.1
24
*
6BA02
NOMESCO Finland
NA
+∞
25.0
23
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
20.4
21.2
32
22
ZX120
NOMESCO Finland
Intravenous
11.4
20.6
42
58
J47
ICD-10 Finland
Bronchiectasis
86.6
19.5
21
*
D80.3
ICD-10 Finland
Selective deficiency of immunoglobulin G [IgG] subclasses
+∞
19.4
18
*
H02AB06
ATC
prednisolone; systemic
7.2
18.5
80
330
TDM10
NOMESCO Finland
Puncture of maxillary antrum
21.0
18.3
27
17
D80.0
ICD-10 Finland
Hereditary hypogammaglobulinaemia
+∞
18.3
17
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
7.7
17.8
49
108
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
10.9
16.9
34
44
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
14.0
15.1
26
24
J01MA12
ATC
levofloxacin; systemic
6.7
14.9
44
103
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.1
14.3
39
81
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
5.5
14.2
53
164
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.2
14.1
69
284
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
11.0
13.9
27
32
J01MA14
ATC
moxifloxacin; systemic
8.6
13.5
31
49
TPH04
NOMESCO Finland
Cathetrisation of vein
5.7
13.2
45
123
UDH02
NOMESCO Finland
Rhinopharyngoscopy
9.9
12.3
25
32
Z01.8
ICD-10 Finland
Other specified special examinations
5.2
12.3
46
138
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
22.2
12.1
17
9
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
11.0
12.0
23
26
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
12.8
11.9
21
20
D80.8
ICD-10 Finland
Other immunodeficiencies with predominantly antibody defects
+∞
11.7
11
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
8.8
11.1
24
34
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
8.3
11.1
25
38
J01FA06
ATC
roxithromycin; oral
4.2
10.8
66
306
J45.8
ICD-10 Finland
Mixed asthma
21.6
10.6
15
8
D69.3
ICD-10 Finland
Idiopathic thrombocytopenic purpura
+∞
10.6
10
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.2
10.5
51
192
J45.1
ICD-10 Finland
Nonallergic asthma
8.4
10.3
23
34
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
8.4
10.3
23
34
R50.9
ICD-10 Finland
Fever, unspecified
5.6
10.2
32
76
SPAT1262
SPAT
Handing over of treatment supplies
5.2
10.0
34
89
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
9.6
9.9
20
25
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
3.9
9.8
72
379
J01FA15
ATC
telithromycin; oral
6.4
9.6
26
51
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
9.8
9.6
19
23
J01FF01
ATC
clindamycin; systemic
3.9
9.4
48
186
WW200
NOMESCO Finland
Immunization
17.7
9.3
14
9
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
4.5
9.1
36
109
J01.0
ICD-10 Finland
Acute maxillary sinusitis
4.1
9.1
41
141
C01CA24
ATC
epinephrine; parenteral
7.2
9.1
22
37
J45.9
ICD-10 Finland
Asthma, unspecified
4.6
9.0
35
104
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.8
8.6
25
54
D86.9
ICD-10 Finland
Sarcoidosis, unspecified
+∞
8.4
8
*
D86.0
ICD-10 Finland
Sarcoidosis of lung
+∞
8.4
8
*
D83.1
ICD-10 Finland
Common variable immunodeficiency with predominant immunoregulatory T-cell disorders
+∞
8.4
8
*
WE300
NOMESCO Finland
Profylactive therapy of malignancy with biomoidiers
+∞
8.4
8
*
UJF32
NOMESCO Finland
Coloscopy
4.1
8.3
37
124
J32.4
ICD-10 Finland
Chronic pansinusitis
36.5
8.2
10
*
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
4.2
8.2
35
113
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
14.6
8.1
13
10
TGC00
NOMESCO Finland
Bronchial lavation
14.6
8.1
13
10
R03AK06
ATC
salmeterol and fluticasone; inhalant
4.7
7.8
28
76
J01MA02
ATC
ciprofloxacin; systemic
3.4
7.8
51
231
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
14.9
7.6
12
9
D86.8
ICD-10 Finland
Sarcoidosis of other and combined sites
+∞
7.4
7
*
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
6.0
7.1
19
37
P01AB01
ATC
metronidazole; oral, rectal
3.1
7.0
55
277
C03CA01
ATC
furosemide; systemic
3.7
6.9
33
116
R03DA04
ATC
theophylline; systemic, rectal
8.8
6.9
14
18
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
3.1
6.9
72
438
R03AC12
ATC
salmeterol; inhalant
9.7
6.8
13
15
J45.0
ICD-10 Finland
Predominantly allergic asthma
4.8
6.6
22
55
J05AB11
ATC
valaciclovir; oral
4.2
6.6
26
77
D70.89
ICD-10 Finland
Neutropenic splenomegaly
74.2
6.5
7
*
ZXA10
NOMESCO Finland
Bilateral
3.8
6.4
29
97
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
19.5
6.4
9
5
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
28.6
6.3
8
*
D59.1
ICD-10 Finland
Other autoimmune haemolytic anaemias
+∞
6.3
6
*
M36.8*D80.1
ICD-10 Finland
Systemic disorders of connective tissue in hypogammaglobulinaemia
+∞
6.3
6
*
129
Kela drug reimbursment
Idiopathic thrombocytopaenia or granulocytopenia
+∞
6.3
6
*
J01DB01
ATC
cefalexin; oral
4.5
6.3
95
727
J02AC01
ATC
fluconazole; systemic
2.9
6.2
56
300
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
3.0
6.2
42
190
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.6
6.2
21
54
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.6
6.1
29
101
D07BA04
ATC
hydrocortisone and antiseptics; topical
4.4
6.1
22
60
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
48
6
131.93
47.15
2.2
1.3
—
—
—
0
0
25
11
28.51
35.01
2.0
1.4
917.0
717.2
e6/l
—
5
6
45
59
11.66
34.90
2.3
1.2
59.4
508.1
u/ml
0.58
26
54
27
23
14.89
27.48
1.9
1.1
—
—
—
0
0
37
57
8.97
24.65
2.6
1.5
—
—
—
0
0
23
18
15.60
24.43
3.4
2.3
—
—
—
0
0
23
21
13.34
22.25
1.4
1.8
—
—
—
0
0
22
19
13.98
21.99
1.5
1.8
—
—
—
0
0
48
127
5.66
18.35
2.9
1.9
—
—
—
0
0
45
114
5.74
18.03
6.5
7.2
1.0
1.1
mmol/l
0.36
45
108
61
206
5.02
17.26
2.9
2.0
3.1
3.2
mg/l
0.04
56
182
15
10
17.02
17.06
2.4
1.0
—
—
—
0
0
15
10
17.02
17.06
2.4
1.0
—
—
—
0
0
42
105
5.64
16.98
2.9
2.6
18.4
24.1
%
1.74
36
89
26
44
7.28
15.54
2.7
1.4
—
—
—
0
0
16
15
12.17
14.97
1.5
1.9
—
—
—
0
0
15
13
13.06
14.71
1.4
1.8
—
—
—
0
0
94
488
5.41
14.39
10.6
6.1
10.5
10.4
umol/l
0.03
94
461
111
726
8.86
13.90
21.9
7.1
94.8
76.8
u/l
3.01
111
675
85
417
4.63
13.81
12.1
8.0
1.2
1.2
mmol/l
0.36
79
359
35
94
4.86
12.69
2.1
1.6
—
—
—
0
0
13
12
12.04
12.17
1.4
1.8
—
—
—
0
0
35
100
4.54
11.67
2.8
2.3
331.9
374.1
nmol/l
0.60
35
94
12
11
12.02
11.24
1.3
1.8
—
—
—
0
0
13
15
9.61
10.43
1.4
1.3
—
—
—
0
0
11
10
12.02
10.31
2.8
1.6
—
—
—
0
0
11
10
12.02
10.31
1.3
1.9
—
—
—
0
0
32
95
4.24
10.04
2.3
1.7
—
—
—
0
0
64
303
3.41
9.95
4.7
3.1
—
—
—
0
0
13
16
9.00
9.93
9.6
2.9
52.9
51.6
%
0.14
13
16
13
16
9.00
9.93
1.4
1.4
—
—
—
0
0
13
16
9.00
9.93
9.2
2.6
3.3
3.9
e9/l
0.43
13
16
13
19
7.56
8.63
1.4
1.4
—
—
—
0
0
64
328
3.06
8.31
2.4
1.9
92.1
98.6
pmol/l
0.36
39
164
10
11
9.83
8.20
1.5
2.1
—
—
—
0
0
15
28
5.99
7.95
3.7
2.5
—
—
—
0
0
50
231
3.01
7.69
1.4
1.3
3.1
2.4
u/ml
—
10
53
12
9
14.65
7.57
2.6
1.7
—
—
—
0
0
12
9
14.65
7.57
1.3
2.0
—
—
—
0
0
14
27
5.74
7.16
3.4
1.3
—
—
—
0
0
11
17
7.03
6.90
3.9
1.4
—
—
—
0
0
78
479
2.82
6.76
5.0
3.2
0.0
0.0
estimate
0.00
23
96
77
472
2.79
6.66
6.4
4.6
0.0
0.0
estimate
0.00
22
96
14
29
5.34
6.64
4.4
2.3
—
—
—
0
0
11
18
6.63
6.55
3.9
1.4
—
—
—
0
0
11
18
6.63
6.55
3.9
1.4
—
—
—
0
0
11
18
6.63
6.55
4.0
1.4
—
—
—
0
0
11
18
6.63
6.55
3.9
1.4
—
—
—
0
0
11
18
6.63
6.55
4.0
1.4
—
—
—
0
0
49
241
2.76
6.53
3.9
3.0
0.6
0.4
e6/l
0.26
41
177
10
7
15.43
6.52
1.4
2.0
—
—
—
0
0
77
478
2.73
6.39
4.8
3.4
0.0
0.0
estimate
0.00
23
90
18
48
4.24
6.36
6.2
3.2
1.8
0.9
mmol/l
0.48
12
33
16
39
4.58
6.31
1.5
2.1
—
—
—
0
0
16
39
4.58
6.31
2.1
1.6
—
—
—
0
0
12
23
5.69
6.15
2.1
2.1
—
—
—
0
0
9
7
13.76
5.68
1.4
1.6
—
—
—
0
0
9
7
13.76
5.68
1.4
1.6
—
—
—
0
0
9
7
13.76
5.68
1.4
1.6
—
—
—
0
0
15
38
4.37
5.63
1.6
1.5
—
—
—
0
0
12
25
5.23
5.63
1.3
1.3
—
—
—
0
0
46
248
2.39
4.82
5.2
3.4
0.0
0.0
estimate
0.00
22
90
53
307
2.31
4.68
4.8
3.0
20.6
39.9
ng/l
0.62
37
174
9
11
8.74
4.65
1.3
1.3
—
—
—
0
0
7
5
14.74
4.63
1.1
1.0
—
—
—
0
0
38
191
2.45
4.62
3.6
2.3
852.2
798.8
ng/l
0.05
33
155
18
61
3.30
4.51
5.8
3.6
1.2
1.2
mmol/l
0.69
18
55
69
452
2.25
4.48
4.6
4.2
—
—
—
0
0
14
42
3.64
4.19
2.7
3.4
25.2
24.9
mmol/l
0.10
14
42
59
371
2.17
4.15
5.2
3.2
—
—
—
0
0
9
15
6.39
3.89
2.6
1.3
—
—
—
0
0
22
92
2.71
3.83
8.6
12.8
0.1
1.7
mmol/l
0.98
15
70
8
12
7.05
3.74
1.0
1.2
—
—
—
0
0
12
35
3.70
3.73
1.3
3.5
—
—
—
0
0
43
249
2.14
3.64
3.3
2.5
7249.5
6054.4
umol/l
0.06
43
219
11
31
3.81
3.57
1.9
1.1
—
—
—
0
0
11
31
3.81
3.57
1.9
1.1
—
—
—
0
0
8
13
6.51
3.56
1.0
1.2
—
—
—
0
0
12
37
3.49
3.44
3.0
1.2
—
—
—
0
0
6
7
8.94
3.30
1.0
1.7
—
—
—
0
0
108
910
3.02
3.26
32.0
10.8
89.3
88.1
ml/min/173m2
0.21
97
748
6
8
7.82
3.09
1.2
1.1
—
—
—
0
0
6
8
7.82
3.09
1.5
2.3
—
—
—
0
0
5
5
10.35
3.00
1.8
1.8
—
—
—
0
0
5
5
10.35
3.00
1.4
1.0
—
—
—
0
0
5
5
10.35
3.00
1.8
1.8
—
—
—
0
0
5
5
10.35
3.00
1.8
1.8
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
5
10.35
3.00
1.0
1.2
—
—
—
0
0
5
5
10.35
3.00
2.6
1.2
44.2
79.8
ug/l
—
5
5
5
5
10.35
3.00
1.8
1.8
—
—
—
0
0
95
766
2.19
3.00
4.3
4.0
14.7
14.7
pmol/l
0.01
90
713
38
224
2.02
3.00
3.4
2.1
—
—
—
0
0
12
41
3.14
2.95
4.3
3.0
46.3
53.3
%
0.31
12
41
6
9
6.95
2.90
1.2
1.3
—
—
—
0
0
5
6
8.63
2.77
1.0
1.2
3.2
3.0
mg/l
—
5
6
5
6
8.63
2.77
3.0
1.0
—
—
—
0
0
17
76
2.44
2.58
3.6
3.1
—
—
—
0
0
6
11
5.68
2.57
1.0
1.2
—
—
—
0
0
5
7
7.39
2.57
7.2
3.1
—
—
—
0
0
102
866
2.24
2.51
43.0
14.9
14.0
13.5
%
2.12
102
857
14
58
2.60
2.47
1.7
1.2
—
—
—
0
0
6
12
5.20
2.43
1.2
1.3
—
—
—
0
0
38
243
1.83
2.29
1.6
1.6
—
—
—
0
0
7
18
4.06
2.29
1.3
1.2
—
—
—
0
0
10
39
2.71
1.97
1.9
3.4
1.7
1.2
%
—
10
39
6
17
3.66
1.86
1.5
1.2
—
—
—
0
0
14
67
2.23
1.84
2.7
2.6
82.9
70.9
ml/min/173m2
—
7
29
8
29
2.88
1.83
1.1
1.1
—
—
—
0
0
7
24
3.03
1.75
1.4
1.6
—
—
—
0
0
89
755
1.71
1.74
4.1
3.5
—
—
—
0
0
29
185
1.75
1.73
1.3
1.3
23.8
46.4
iu/ml
—
5
62
13
62
2.23
1.73
6.2
1.9
71.2
120.0
ng/l
0.86
13
54
23
139
1.81
1.63
2.5
2.8
1.5
2.6
e6/l
0.60
11
71
5
14
3.68
1.63
2.2
1.3
—
—
—
0
0
34
232
1.65
1.59
1.7
1.9
0.7
0.6
mg/l
0.18
26
174
27
174
1.71
1.55
5.4
3.2
17.8
130.4
ng/l
1.04
17
111
28
192
1.60
1.27
1.4
1.3
1.1
6.5
u/ml
1.69
12
79
5
21
2.44
1.10
1.2
1.5
—
—
—
0
0
5
21
2.44
1.10
1.2
1.5
—
—
—
0
0
22
149
1.58
1.05
2.2
2.7
2.0
0.8
e6/l
—
10
81
13
80
1.70
0.89
1.9
1.3
11.3
130.2
iu/ml
—
6
33
0
25
0.00
0.80
0.0
1.3
—
—
—
0
0
7
39
1.84
0.74
1.6
1.2
—
—
—
0
0
5
28
1.82
0.67
1.4
1.4
—
—
—
0
0
0
20
0.00
0.61
0.0
1.4
—
—
—
0
0
6
37
1.65
0.56
1.7
1.5
—
—
—
0
0
6
38
1.61
0.55
1.2
1.7
—
—
—
0
0
13
94
1.43
0.48
2.8
2.1
—
—
—
0
0
11
80
1.41
0.40
2.5
1.9
—
—
—
0
0
5
79
0.62
0.37
1.6
1.5
—
—
—
0
0
5
39
1.29
0.23
1.0
1.4
—
—
—
0
0
5
39
1.29
0.23
1.4
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
13
110
1.20
0.18
8.5
6.6
—
—
—
0
0
19
210
0.89
0.13
1.4
1.4
—
—
—
0
0
19
178
1.08
0.06
3.1
2.2
—
—
—
0
0
18
169
1.08
0.05
3.2
2.0
—
—
—
0
0
18
169
1.08
0.05
3.2
3.9
26.3
24.0
%
—
8
69
99
980
1.06
0.04
4.3
4.5
2.7
2.8
mmol/l
0.76
93
924
10
103
0.97
0.00
4.9
4.2
30.7
31.3
%
—
10
69
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
10.2
—
0
5
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
6
61
0.98
0.00
1.2
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_CVIDNAS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have D3_CVIDNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: D3_CVIDNAS – Other or unspecified common variable immunodeficiency
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data